GLP-1 Receptor Agonists Are Safe for Patients with Melanoma In Situ
Yes, a patient with a history of melanoma in situ can safely take GLP-1 receptor agonists. The absolute contraindication for GLP-1 RAs applies only to medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), not to melanoma or other skin cancers 1, 2.
Evidence Supporting Safety in Melanoma
The most robust evidence comes from a 2024 population-based cohort study of 11,786 GLP-1 RA users compared with 208,519 sulfonylurea users, which found no increased risk of melanoma (42.6 vs. 43.9 per 100,000 person-years; HR 0.96,95% CI 0.53-1.75) 3. This study specifically examined melanoma as a separate outcome and found no association even with cumulative duration of use 3.
A 2019 meta-analysis of 50,452 patients across 34 randomized controlled trials confirmed no increase in malignant neoplasm formation with GLP-1 RAs (OR 1.04,95% CI 0.94-1.15) 4. Furthermore, a 2024 study examining 13 obesity-associated cancers in 1.65 million patients with type 2 diabetes found that GLP-1 RAs were not associated with increased cancer risk and actually showed protective effects for multiple cancer types 5.
Specific Contraindications to Verify
Before prescribing, screen for the actual contraindications 1, 2, 6:
- Personal or family history of medullary thyroid carcinoma (absolute contraindication)
- Multiple endocrine neoplasia syndrome type 2 (absolute contraindication)
- Severe hypersensitivity reaction to the specific GLP-1 RA (absolute contraindication)
Melanoma in situ does not appear on any contraindication list for GLP-1 receptor agonists 6, 7.
Clinical Algorithm for This Patient
For a patient with melanoma in situ history:
- Confirm the melanoma diagnosis was in situ (not invasive) and has been completely excised
- Screen for MTC/MEN2 contraindications (personal or family history) 2, 6
- Proceed with standard GLP-1 RA prescribing if no contraindications exist 6
- Follow routine dermatologic surveillance for melanoma recurrence per standard guidelines (not related to GLP-1 RA use) 6
- Monitor for actual GLP-1 RA safety concerns: gastrointestinal effects, gallbladder disease, pancreatitis, and tachycardia 1, 2
Medication Selection
Choose the GLP-1 RA based on clinical indication, not melanoma history 2, 6:
- For type 2 diabetes with obesity: Tirzepatide 15mg weekly achieves 20.9% weight loss 2
- For established cardiovascular disease: Semaglutide 2.4mg weekly provides 26% reduction in CV death/MI/stroke (HR 0.74) 2, 6
- For obesity without diabetes: Semaglutide 2.4mg weekly achieves 14.9% weight loss with proven CV benefit 2, 8
Common Pitfall to Avoid
Do not unnecessarily withhold GLP-1 RAs based on melanoma history. The FDA Black Box Warning specifically addresses thyroid C-cell tumors (medullary thyroid carcinoma), not melanoma or other skin cancers 6. Major cardiovascular guidelines do not identify melanoma or other non-MTC cancers as safety concerns with GLP-1 RA therapy 6.